Company Profile: Pfizer Inc. (PFE)

PFE insider trades (13 months) →

$30.00 −2.18% vs. previous close · Market cap $170.99B

Today's multi-factor rank: 307 of 461 · see the ranking

Quant500 Scores

Momentum

5.3/10

Value

5.0/10

Growth

3.5/10

Quality

5.0/10

Multifactor

4.7/10

Market and Valuation

Price & Market

Prev Close Price:$30.67

Open:$30.68

Day's Low:$29.89

Day's High:$31.05

Bid / Ask:-

Market Cap:170.99B

Enterprise Value:226.89B

52-Week Range

52-Week Low:$23.62

52-Week High:$31.05

Current position in 52-week range

52w Low-52w High

50-Day Avg:$28.60

200-Day Avg:$26.82

Volume

Volume Today:52,747,281

Avg Volume (3m):33,911,743

Avg Volume (10d):32,380,880

52-Week Change:+26.21%

vs S&P 500, 52 weeks:-

Beta:0.30

Valuation Multiples

P/E (trailing):42.86

Diluted EPS for the last 12 months: the four quarters ended Sep 27, 2026, from the accounts filed with the SEC on Nov 3, 2026. The P/E is the price divided by that EPS.

P/E (forward):10.36

PEG Ratio:14.05

Price / Book:2.01

Price / Sales (TTM):2.68

EV / Revenue:3.56

EV / EBITDA:8.94

Dividends

Current yield:5.61%

Annual Dividend Rate:$1.72

Dividend Trailing:$1.72

Yield Trailing:5.61%

5-Year Avg Yield:4.79%

Payout Ratio:226.32%

Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-

Fiscal Year (Next):-

Date Filter (Month):

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):63.70B

Gross Profit:47.59B

EBITDA:25.38B

Net Income (TTM):4.34B

Rev Growth (YoY):+2.60%

Earnings Growth (YoY):-

Quarterly earnings growth (YoY):-

Margins

Gross Margin:-

EBITDA Margin:-

Operating Margin:-

Net Margin:-

Per Share

EPS Trailing (TTM):$0.70

Diluted EPS for the last 12 months: the four quarters ended Sep 27, 2026, from the accounts filed with the SEC on Nov 3, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$2.89

Revenue Per Share:$11.19

Cash Per Share:-

Book Value:$14.95

Last Dividend:-

Ex-Dividend Date:-

Last Split:-

Balance Sheet & Liquidity

Total cash:11.70B

Total Debt:63.48B

Net Debt (Debt - Cash):51.78B

Debt / Equity:74.25%

Current Ratio:1.27

Quick Ratio:0.85

Cash Flows

Operating Cash Flow:13.40B

Free Cash Flow (FCF):12.49B

FCF Yield (FCF / Market Cap):-

Enterprise Value:226.89B

EV / Revenue:3.56

EV / EBITDA:8.94

Profitability

ROE (Return on Equity):5.01%

ROA (Return on Assets):5.78%

P/E (trailing):42.86

P/E (forward):10.36

Price / Book:2.01

PEG Ratio:14.05

52-Week Change:+26.21%

S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$0.70

Diluted EPS for the last 12 months: the four quarters ended Sep 27, 2026, from the accounts filed with the SEC on Nov 3, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$2.89

P/E (forward):10.36

PEG Ratio:14.05

Growth and Margins

Earnings Growth YoY:-

Quarterly Earnings Growth YoY:-

Rev Growth YoY:-

Net Margin:-

Gross Margin:-

EBITDA Margin:-

Per Share

Revenue Per Share:$11.19

Cash Per Share:-

Book Value:$14.95

Cash Flows (TTM)

Free Cash Flow:12.49B

Operating Cash Flow:13.40B

EBITDA:25.38B

Total Revenue (TTM):63.70B

Net Income (TTM):4.34B

Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter	Period	Actual EPS	Estimated EPS	Difference	Surprise %	Currency

Ownership Structure

Ownership Distribution

% Insiders:-

% Institutional:-

% Inst. (of Float):-

No. of Institutions:-

Visual distribution

InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:5,699,673,589

Float (free shares):5,692,264,013

Short interest (shares):137,816,093

Short % of float:-

Short Ratio (days to cover):4.20

Short interest, prior month:-

Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-

Audit Risk:-

Board risk:-

Compensation Risk:-

Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization	Report Date	% Shares	No. Shares	Value (USD)	Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund	Report Date	% Shares	No. Shares	Value (USD)	Change %

Recent Insider Trades

Executive / Insider	Title	Date	Action	Shares

Options Chain

Expiration Date:

CALLS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

PUTS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

Pfizer Inc. (PFE) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type	Date	Official link
8-K	2026-11-03	View filing ↗
N-PX	2026-08-31	View filing ↗
8-K	2026-08-04	View filing ↗
8-K	2026-06-18	View filing ↗
11-K	2026-06-16	View filing ↗
S-8	2026-05-05	View filing ↗
8-K	2026-04-27	View filing ↗
ARS	2026-03-12	View filing ↗
10-K	2026-02-26	View filing ↗
8-K	2026-02-03	View filing ↗

Company and Executive Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

General Information

Headquarters:United States

City:New York

Employees:75,000

Sector:Healthcare

Industry:Drug Manufacturers - General

Website:-

Key Executives

Name	Title	Age	Total pay
Dr. Albert Bourla D.V.M., Ph.D.	Chairman of the Board & CEO	63	9.14M
Dr. Chris Boshoff FMedSci, M.D., Ph.D.	Chief Scientific Officer and President of Research & Development	61	5.20M
Mr. Douglas M. Lankler	Executive VP & Chief Legal Officer	59	4.62M
Mr. Aamir Malik	Executive VP & Chief U.S. Commercial Officer	49	4.90M
Ms. Cecile Guegan	Interim CFO & Executive VP	54	-
Ms. Jennifer B. Damico	Senior VP, Controller & Principal Accounting Officer	56	-
Mr. Dennis P. Hancock	Executive VP & Chief Information Officer	-	-
Ms. Francesca M. DeMartino	Chief Investor Relations Officer	-	-

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

Pfizer Inc. (PFE): Quantitative Analysis

Name: Factor scores for Pfizer Inc. (PFE)
Creator: Quant500
License: https://quant500.com/legal

Pfizer Inc. (PFE) — Healthcare — Drug Manufacturers - General. PFE is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, PFE has returned +25.7% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

PFE ranks 307 of 461 on today's multifactor score, and 41 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 0.20, ranked 178 of 494); its weakest is growth (Z -0.89, ranked 471 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

Factor	Z-Score	Rank
Multifactor	-0.179	307 of 461
Momentum	0.200	178 of 494 ↓30
Value	-0.023	210 of 489
Quality	-0.003	210 of 468
Growth	-0.892	471 of 489

Market data

Metric	Value
Price	$30.00
Market Cap	170.99B
P/E	42.86
Revenue (last 12 months)	63.70B
Price / book	2.01
Book value per share	$14.95
52-week range	$23.62 – $31.05
Dividend yield	5.61%
Beta	0.30
Average volume	33,911,743
Shares outstanding	5.70B
Short interest (% of float)	2.42% (as of Oct 15, 2026)

When does PFE report earnings? 12 of its last 12, before the open →

What are PFE insiders doing? 26 transactions filed with the SEC, of them 3 buys and 2 sells, the last one on Aug 12, 2026 →

PFE latest SEC filings

Annual report (10-K): filed Feb 26, 2026, fiscal year ended Dec 31, 2025 · view the filing on sec.gov
Quarterly report (10-Q): filed Nov 3, 2026, quarter ended Sep 27, 2026 · see its 10-Q filings on sec.gov
Earnings release (8-K): Nov 3, 2026, before the open · view the 8-K on sec.gov

Filing dates on EDGAR, the SEC's public registry. All PFE filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about Pfizer (PFE)

When does Pfizer report earnings?

Pfizer has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Nov 3, 2026). PFE earnings dates and times, quarter by quarter →

What is Pfizer's P/E ratio?

Pfizer's P/E (price over earnings per share for the last twelve months) is 42.9 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 27, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Pfizer is above its sector median. Healthcare stocks, company by company →

Where does Pfizer rank on Quant500?

In the Nov 3, 2026 multi-factor ranking, Pfizer ranks 307 of 461, and 41 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking → How it is calculated →

Have Pfizer insiders bought or sold shares?

The latest open-market purchase of Pfizer shares filed with the SEC (Form 4) was on Aug 12, 2026, by a director who is also an officer, for $1.0M. The latest sale was on Aug 5, 2026, by an officer, for $83k. In total, from August 2025 through Nov 3, 2026: 3 purchases and 2 sales by directors, officers and large shareholders. All PFE insider trades →

Does Pfizer pay a dividend?

Yes. Its dividend yield is 5.61% at the Nov 3, 2026 close (annual dividend of $1.72 per share). The next announced ex-dividend date is Nov 6, 2026.

What sector is Pfizer in, and which index?

Pfizer is classified in the Healthcare sector (industry: Drug Manufacturers - General), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

Valuation multiples: P/E, P/B, EV/EBITDA and their trapsWhy the P/E and the price-to-book in the table above cannot be compared across sectors, and what a low P/E can hide.
Value and momentum: the two that have survived bestWhat the value and momentum scores on this page actually measure, and why they are the two factors that have best survived scrutiny.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
Sales growth: the driver that gets overestimated mostWhat sits behind the growth score and the twelve-month revenue, and why it is the number people extrapolate too far most often.
Dividends and payout: high is not always goodThis company pays a dividend and its yield is in the table above: when a high figure is good news and when it is a warning.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

Company Profile: Pfizer Inc. (PFE)

Market and Valuation

Price & Market

52-Week Range

Volume

Valuation Multiples

Dividends

Valuation Context

Financial Statements TTM (Trailing 12 Months)

Income Statement

Margins

Per Share

Balance Sheet & Liquidity

Cash Flows

Profitability

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

Growth and Margins

Per Share

Cash Flows (TTM)

EPS Surprise History - Last 4 Quarters

Ownership Structure

Ownership Distribution

Shares & Short Interest

Governance Score (1=Best, 10=Worst)

Top Institutional Holders

Top Mutual Funds

Recent Insider Trades

Options Chain

CALLS

PUTS

Sentiment Metrics

Expected move

Pfizer Inc. (PFE) SEC filings: 10-K, 10-Q and 8-K

Company and Executive Profile

General Information

Key Executives

You have seen the engine room

Pfizer Inc. (PFE): Quantitative Analysis

Factor scores

Market data

PFE latest SEC filings

Frequently asked questions about Pfizer (PFE)

When does Pfizer report earnings?

What is Pfizer's P/E ratio?

Where does Pfizer rank on Quant500?

Have Pfizer insiders bought or sold shares?

Does Pfizer pay a dividend?

What sector is Pfizer in, and which index?

What is behind these numbers